News | February 29, 2024
Bajaj Healthcare enters into definitive CDMO Agreement for 15 APIs with UK/EU customers
BHL will undertake the development and supply of these molecules
BHL will undertake the development and supply of these molecules
The plant will drive pharmaceutical innovation in the Northeastern India
Academic and Policy Research to get further boost, RIS will bring forth Ayush Service Sector report soon
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Subscribe To Our Newsletter & Stay Updated
